| Literature DB >> 25082897 |
David Gate1, Moise Danielpour2, Javier Rodriguez3, Gi-Bum Kim4, Rachelle Levy4, Serguei Bannykh5, Joshua J Breunig4, Susan M Kaech6, Richard A Flavell7, Terrence Town8.
Abstract
Cancer cell secretion of TGF-β is a potent mechanism for immune evasion. However, little is known about how central nervous system tumors guard against immune eradication. We sought to determine the impact of T-cell TGF-β signaling blockade on progression of medulloblastoma (MB), the most common pediatric brain tumor. Genetic abrogation of T-cell TGF-β signaling mitigated tumor progression in the smoothened A1 (SmoA1) transgenic MB mouse. T regulatory cells were nearly abolished and antitumor immunity was mediated by CD8 cytotoxic T lymphocytes. To define the CD8 T-cell subpopulation responsible, primed CD8 T cells were adoptively transferred into tumor-bearing immunocompromised SmoA1 recipients. This led to generation of CD8(+)/killer cell lectin-like receptor G1 high (KLRG1(hi))/IL-7R(lo) short-lived effector cells that expressed granzyme B at the tumor. These results identify a cellular immune mechanism whereby TGF-β signaling blockade licenses the T-cell repertoire to kill pediatric brain tumor cells.Entities:
Keywords: cancer immunology; neuro-oncology; neuroimmunology
Mesh:
Substances:
Year: 2014 PMID: 25082897 PMCID: PMC4143044 DOI: 10.1073/pnas.1412489111
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205